ABP

Abpro Corporation develops novel antibody therapeutics for oncology and ophthalmology, leveraging platforms such as DiversImmune to engineer advanced antibody constructs. The company’s core focus is on creating highly specific and effective biological treatments that address significant unmet medical needs in these complex disease areas. Their technical approach centers on developing powerful antibody technologies aimed at precise targeting and improved patient outcomes.

The company was co-founded in 2004 by brothers Ian Chan and Eugene Chan, M.D. Ian Chan assumed the role of Chief Executive Officer, while Eugene Chan, with his medical background, served as Chairman. Their combined insight stemmed from a shared imperative to design potent antibody therapeutics, recognizing the potential of these molecules to transform the treatment landscape for severe conditions.

Abpro's products are ultimately intended for patients suffering from diseases in immuno-oncology and ophthalmology, with potential applications for pharmaceutical partners seeking innovative solutions. The company's long-term vision is to accelerate the development and delivery of transformative antibody therapies, aiming to significantly improve the treatment paradigm for various severe diseases, including cancer.